Understanding how HPV interacts with the body's DNA damage response
Interplay between the cellular DNA damage response and the HPV life cycle
This study is looking at how high-risk HPV infections affect the way our cells handle DNA damage, with the goal of finding new treatments for cancers caused by HPV, so that patients can have better options for managing their health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Univ of North Carolina Chapel Hill NIH-funded |
| Lab location | 1 site (Chapel Hill, United States) |
| Project ID | NIH-11066532 on NIH RePORTER |
What this research studies
This research investigates the relationship between high-risk human papillomavirus (HPV) infections and the cellular mechanisms that respond to DNA damage. By studying how HPV manipulates the DNA damage response to enhance its own replication, the research aims to uncover new therapeutic strategies for treating HPV-related cancers. The approach involves examining the roles of specific proteins, such as RNF168 and BRCA1, in the viral life cycle and how they may be targeted for antiviral drug development. Patients may benefit from insights that could lead to effective antiviral therapies for HPV-related diseases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with persistent high-risk HPV infections or HPV-related cancers.
Not a fit: Patients who do not have HPV infections or related cancers are unlikely to benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of novel antiviral treatments for cancers caused by HPV.
How similar studies have performed: Previous research has shown promise in targeting viral interactions with the DNA damage response, suggesting potential for success in this area.
Where this research is happening
Chapel Hill, United States
- Univ of North Carolina Chapel Hill — Chapel Hill, United States (Active)
Researchers
- Principal investigator: Moody, Cary a — Univ of North Carolina Chapel Hill
- Study coordinator: Moody, Cary a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.